As current treatments for peripheral vascular diseases in humans are limited in effectiveness, this JNK3–Foxo3a–Egr1/Creb1 pathway may serve as a promising target for therapies aiming to improve the peripheral vasculature in diabetic and other affected patient populations. Here, MAPK10 is linked to peripheral vascular disease.